EP1090107A1 - Menschliche monoklonale antikörper gegen das tumor-antigen uk114 sowie lymphozyten und hybrodomas zur deren herstellung - Google Patents
Menschliche monoklonale antikörper gegen das tumor-antigen uk114 sowie lymphozyten und hybrodomas zur deren herstellungInfo
- Publication number
- EP1090107A1 EP1090107A1 EP99931141A EP99931141A EP1090107A1 EP 1090107 A1 EP1090107 A1 EP 1090107A1 EP 99931141 A EP99931141 A EP 99931141A EP 99931141 A EP99931141 A EP 99931141A EP 1090107 A1 EP1090107 A1 EP 1090107A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- antibodies
- hybridomas
- monoclonal antibodies
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 21
- 239000000427 antigen Substances 0.000 title claims abstract description 11
- 108091007433 antigens Proteins 0.000 title claims abstract description 11
- 102000036639 antigens Human genes 0.000 title claims abstract description 11
- 210000004408 hybridoma Anatomy 0.000 title claims description 20
- 210000004698 lymphocyte Anatomy 0.000 title description 8
- 238000004519 manufacturing process Methods 0.000 title description 3
- 210000004027 cell Anatomy 0.000 claims description 35
- 230000004927 fusion Effects 0.000 claims description 9
- 230000003248 secreting effect Effects 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 241001529936 Murinae Species 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 230000000527 lymphocytic effect Effects 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- -1 diagnostics Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 206010009944 Colon cancer Diseases 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000166550 Strophanthus gratus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940043517 specific immunoglobulins Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Definitions
- the present invention refers to human monoclonal antibodies against the tumor antigen UKl 14, to immortalized lymphocytes and to hybridomas secreting said antibodies.
- Antibodies specific for the UKl 14 protein have been isolated from the sera of cancer patients and in many cases the specific antibody titer turned out to be significantly increased in patients treated with UKl 01 , the drug containing as the active component the heterologous UKl 14 protein (Bartorelli, A., et al., J. Tumor
- the antibodies of interest have been analyzed on a panel of tumor cell-lines of different origin and of normal cells so as to evaluate the selective recognition of the tumor-associated antigen.
- the human antibodies in addition to the purified native protein, all recognized a membrane antigen expressed on gastric tumors (HT-29, Kato III), colon tumors (Colo 684, LoVo), breast tumors (MCF-7, MDA), and on some neuroblastomas (LAN-1, SY5Y) as well as on breast and lung tumors from patients subjected to surgery.
- a first embodiment of the invention refers therefore to the human monoclonal antibodies directed against the UKl 14 protein.
- a second embodiment of the invention refers to immortalized lymphocyte cells secreting the monoclonal antibodies against UKl 14.
- EBV-immortalized cells having the drawbacks of instability and low yield in produced antibody
- human hybridomas were obtained.
- Said lines yield generally more stable hybridomas, able to better grow in nude mice in form of ascitic tumor.
- Three EBV lines selected on the basis of their growing characteristics were fused with the hetero-myeloma K6H6 (Carrol, WL, et al., J. Immunol. Meth. 89:61-69, 1986) obtainable from ATCC and the obtained clones were analyzed for reactivity against the UKl 14 antigen by an ELISA method. The fusion system was very efficient and more than 70% of the obtained clones were reactive.
- the selected hybridomas were expanded in vitro and cloned by limit dilution.
- the final result was the selection of three hybridomas: UK#l/2G3hy, UK#l/lAl lhy and UK#l/3D8hy.
- the first two hybridomas are of IgM-k isotype and the third of IgM- ⁇ .
- the hybridomas maintained the tumor specificity characteristic of the parental lines, as shown in the following Table:
- MCF-10 non-malignant breast
- the reactivity of human monoclonal antibodies on the different tumor lines also showed high differences in terms of number of positive cells and of fluorescence intensity thereby suggesting that different epitopes, recognized by the tree reagents, exist on the target antigen expressed on the membrane, as showed in figure.
- the three hybridomas have been adapted to grow in vivo in nulnu mice and so are able to grow as ascites tumor, and this allows to increase the specific immunoglobulin concentration of some order of magnitude. Then, the hybridomas have been adapted to grow in synthetic serum-free medium: a main stage to purify antibody eventually destined to clinical use.
- a further object of the invention refers to human hybridomas that are able to secrete anti UKl 14 human monoclonal antibodies.
- One of such hybridomas (UK#1/3D8) was deposited at ECACC (European Collection of Cell Cultures) under n° 9706 2409 on June 24 th , 1997.
- the human antibodies herein described are an optimal clinic/diagnostic tool: first of aspect at present all, they permit to test the human antibody answers to the UKl 01 treatment, at present unknown and different from what is reproducible in the animal models; secondly, the produced reagents could be used in diagnostics as vectors of radioactive isotopes useful in radio-pilot surgery, or in therapy as toxins or drugs vectors.
- the antibodies of the invention do not cause the undesirable side effects typical of the murine reagents, as they are of human nature.
- the following example shows in more detail the steps for the preparation of the immortalized cells, of the hybridomas and of the ascitis, as well as the functional characteristics belonging to the lytic power, i) B cell immortalization Human B cells purified from peripheral blood from a carcinoma lung cancer patient successfully treated with UK101 , were enriched by conventional density gradient. The T lymphocytes were removed from the resulting lymphocytic cells by rosetting with sheep erythrocytes. The purified B cells (10 7 ml) were infected by incubation with Epstain Barr virus (EBV) obtained from the B95--8 cell line (10% in the colture medium).
- EBV Epstain Barr virus
- lymphoblastoid cell lines three were selected, on the basis of the best growth and secretion characteristics, to be used as partner in the somatic fusion with the myeloma. Since the availability of suitable human myeloma as tumor partners in the cell fusion is very scarce and the products resulting are also very unstable, an hetero-myeloma cell line (human- mouse) provided from ATCC able to fuse with high efficiency and with a better products stability was selected.
- the used cell line (K6H6/B5) was obtained from the fusion of a murine myeloma with normal human B lymphocytes and selected for being non-secreting and aminopterin-sensitive.
- the EBV cell lines were fused, in a 2: 1 ratio, with the K6H6/B5 line using polyethylene glycol (pH 7) as promoter agent following a conventional technique. After the fusion the cells were plated on irradiated allogenic lymphocytes constituting the support cells. After 24 hours the selectors were added in the following ratio: hypoxanthine l OO ⁇ M, aminopterin 800nM, thymidine 15 ⁇ M, ouabain 0.1 ⁇ M.
- KATO III gastric carcinoma
- MOG-G-UVW astrocytoma
- HT-29 colon carcinoma selected as tumor target
- 3,7 MBq of Na 2 [ 51 C R ]0 4 for 1 hour at 37°C.
- the cells were incubated at 37°C for 1 ,5 hour in the presence of the human antibodies anti-UK114 (ascites diluted 1 : 10) and of 10 ⁇ l of human serum.
- human serum deprived of C8 C9 factors, or heat-inactivated were used.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI981467 | 1998-06-26 | ||
| IT98MI001467 IT1301815B1 (it) | 1998-06-26 | 1998-06-26 | Anticorpi monoclonali umani contro l'antigene tumorale uk114 e cellulelinfocitarie e ibridomi per la loro produzione |
| PCT/EP1999/004333 WO2000000591A1 (en) | 1998-06-26 | 1999-06-23 | Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cells and hybridomas for their production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1090107A1 true EP1090107A1 (de) | 2001-04-11 |
Family
ID=11380330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP99931141A Withdrawn EP1090107A1 (de) | 1998-06-26 | 1999-06-23 | Menschliche monoklonale antikörper gegen das tumor-antigen uk114 sowie lymphozyten und hybrodomas zur deren herstellung |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1090107A1 (de) |
| JP (1) | JP2002519020A (de) |
| AU (1) | AU4775899A (de) |
| CA (1) | CA2331762A1 (de) |
| IT (1) | IT1301815B1 (de) |
| WO (1) | WO2000000591A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5825701A (en) * | 2000-03-03 | 2001-09-12 | Zetesis S.P.A | A novel tumor-related antigen |
| IT201600127428A1 (it) * | 2016-12-16 | 2018-06-16 | Cusani Alberto Bartorelli | Nuova proteina ricombinante uk 114 in forma stabile polimerica per uso nella terapia, nella diagnostica e nella prevenzione di neoplasie maligne |
-
1998
- 1998-06-26 IT IT98MI001467 patent/IT1301815B1/it active IP Right Grant
-
1999
- 1999-06-23 AU AU47758/99A patent/AU4775899A/en not_active Abandoned
- 1999-06-23 WO PCT/EP1999/004333 patent/WO2000000591A1/en not_active Application Discontinuation
- 1999-06-23 EP EP99931141A patent/EP1090107A1/de not_active Withdrawn
- 1999-06-23 JP JP2000557344A patent/JP2002519020A/ja active Pending
- 1999-06-23 CA CA002331762A patent/CA2331762A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0000591A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002519020A (ja) | 2002-07-02 |
| AU4775899A (en) | 2000-01-17 |
| WO2000000591A1 (en) | 2000-01-06 |
| CA2331762A1 (en) | 2000-01-06 |
| IT1301815B1 (it) | 2000-07-07 |
| ITMI981467A1 (it) | 1999-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4434156A (en) | Monoclonal antibodies specific for the human transferrin receptor glycoprotein | |
| US4828991A (en) | Tumor specific monoclonal antibodies | |
| US4350683A (en) | Antibody production from hybrid cell line | |
| US4892935A (en) | Anti-human pulmonary carcinoma monoclonal antibody | |
| AU612967B2 (en) | Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas | |
| US4613576A (en) | Human monoclonal antibodies to cancer cells | |
| JPH0198478A (ja) | ＩｇＧモノクローナル抗体−生産性ハイブリドマ | |
| JPH0159870B2 (de) | ||
| SK279249B6 (sk) | Ľudské monoklonálne protilátky a spôsob ich výroby | |
| JPS63294779A (ja) | ハイブリドマ | |
| JP2002507398A (ja) | ヒト・モノクローナル抗体およびそのための使用の開発 | |
| JPH0159869B2 (de) | ||
| US5024946A (en) | Human monoclonal antibody to antigen of gastric cancer and B-cell line for producing this antibody, method for preparing this B-cell line and antibody, antigen and method of preparation of this antigen | |
| US5106738A (en) | Tumor specific monoclonal antibodies | |
| EP0156578A2 (de) | Verfahren zur Herstellung von tumorspezifische monoklonale Antikörper produzierenden Hybridomazellen | |
| EP0328578B1 (de) | Von mca 16-88 erkanntes antigen | |
| WO2000000591A1 (en) | Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cells and hybridomas for their production | |
| JP4563573B2 (ja) | 抗原およびこの抗原を識別するモノクローナル抗体 | |
| YOSHIKAWA et al. | Human monoclonal antibody reactive to stomach cancer produced by mouse-human hybridoma technique | |
| JP4493882B2 (ja) | 抗原およびこの抗原を識別するモノクローナル抗体 | |
| SUGIYAMA et al. | Preparation of human monoclonal antibodies of IgG type to gastro-intestinal cancer-associated antigen | |
| JPS59128397A (ja) | 抗ヒト胃癌抗体 | |
| Cote et al. | The generation of human monoclonal antibodies and their use in the analysis of the humoral immune response to cancer | |
| JP2845568B2 (ja) | モノクローナル抗体 | |
| Gupta et al. | Isolation of human monoclonal antibodies binding to B fragment of diphtheria toxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20010111 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20030627 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20031108 |